Detalles de la búsqueda
1.
Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase.
Cell
; 144(5): 703-18, 2011 Mar 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-21376233
2.
MIMESIS: minimal DNA-methylation signatures to quantify and classify tumor signals in tissue and cell-free DNA samples.
Brief Bioinform
; 24(2)2023 03 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-36653909
3.
Circulating tumor cells and palbociclib treatment in patients with ER-positive, HER2-negative advanced breast cancer: results from a translational sub-study of the TREnd trial.
Breast Cancer Res
; 23(1): 38, 2021 03 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-33761970
4.
Precision Oncology via NMR-Based Metabolomics: A Review on Breast Cancer.
Int J Mol Sci
; 22(9)2021 Apr 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-33925233
5.
Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial.
Breast Cancer Res
; 21(1): 71, 2019 05 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-31142370
6.
ddSeeker: a tool for processing Bio-Rad ddSEQ single cell RNA-seq data.
BMC Genomics
; 19(1): 960, 2018 Dec 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-30583719
7.
A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients.
Breast Cancer Res Treat
; 170(2): 329-341, 2018 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-29564743
8.
Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers.
BMC Med
; 13: 46, 2015 Mar 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-25857348
9.
Cyclin-dependent kinase 4/6 inhibitors in breast cancer therapy.
Curr Opin Oncol
; 26(6): 568-75, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25188473
10.
Mutational Analysis of Circulating Tumor DNA in Patients With Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer Receiving Palbociclib: Results From the TREnd Trial.
JCO Precis Oncol
; 8: e2300285, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38427931
11.
Elevated nuclear expression of the SMRT corepressor in breast cancer is associated with earlier tumor recurrence.
Breast Cancer Res Treat
; 136(1): 253-65, 2012 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-23015261
12.
Upregulation of mucin4 in ER-positive/HER2-overexpressing breast cancer xenografts with acquired resistance to endocrine and HER2-targeted therapies.
Breast Cancer Res Treat
; 134(2): 583-93, 2012 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-22644656
13.
The p160 ER co-regulators predict outcome in ER negative breast cancer.
Breast Cancer Res Treat
; 131(2): 463-72, 2012 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-21390497
14.
PIK3CA co-occurring mutations and copy-number gain in hormone receptor positive and HER2 negative breast cancer.
NPJ Breast Cancer
; 8(1): 24, 2022 Feb 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-35181669
15.
Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant.
Eur J Cancer
; 164: 39-51, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35172272
16.
CDK4/6 inhibitors: A focus on biomarkers of response and post-treatment therapeutic strategies in hormone receptor-positive HER2-negative breast cancer.
Cancer Treat Rev
; 93: 102136, 2021 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-33360919
17.
Charting differentially methylated regions in cancer with Rocker-meth.
Commun Biol
; 4(1): 1249, 2021 11 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34728774
18.
Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer.
Cancers (Basel)
; 13(11)2021 May 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-34072070
19.
A Serum Metabolomics Classifier Derived from Elderly Patients with Metastatic Colorectal Cancer Predicts Relapse in the Adjuvant Setting.
Cancers (Basel)
; 13(11)2021 Jun 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34199435
20.
Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer.
Clin Cancer Res
; 27(17): 4870-4882, 2021 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33536276